Avalo TherapeuticsAVTX +6.22%23 PS Ratio is 6,426.67 as of Jun. 30, 2026, which is 43206% above its 10-year median of 14.84. GuruFocus rates AVTX with a GF Score™ of 23/100 and a GF Value™ of $0.03 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 935 Biotechnology companies, Avalo Therapeutics ranks worse than 99.47% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Avalo Therapeutics's share price is $19.28.
Avalo Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00. Hence, Avalo Therapeutics's PS Ratio for today is 6,426.67.
The historical rank and industry rank for Avalo Therapeutics's PS Ratio or its related term are showing as below:
AVTX'
s PS Ratio Range Over the Past 10 Years
Min: 0.05 Med: 14.84 Max: 7190
Current: 6426.67
During the past 13 years, Avalo Therapeutics's highest PS Ratio was 7190.00. The lowest was 0.05. And the median was 14.84.
AVTX's PS Ratio is ranked worse than 99.47% of 935
companies
in the Biotechnology industry
Industry Median: 9.37
vs AVTX: 6426.67
Avalo Therapeutics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Avalo Therapeutics was -92.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -97.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -90.90% per year.
During the past 13 years, Avalo Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 5.40% per year. The lowest was -97.90% per year. And the median was -58.10% per year.
Back to Basics: PS Ratio
Avalo Therapeutics (NAS:AVTX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Avalo Therapeutics PS Ratio Related Terms
Avalo Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Avalo Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Avalo Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avalo Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Avalo Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Avalo Therapeutics's Share Price of today is $19.28. Avalo Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Avalo Therapeutics (AVTX) has a PS Ratio of 6,426.67 as of Jun. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Avalo Therapeutics and its competitors. This is 43206% above median its historical median of 14.84. Over the past decade, Avalo Therapeutics' PS Ratio has ranged from 0.05 to 7,190.00. According to the industry distribution chart, Avalo Therapeutics ranks #930 out of 935 companies in the Biotechnology industry, placing it in the top 99.5%.
Is Avalo Therapeutics' PS Ratio too high?
Avalo Therapeutics' current PS Ratio of 6,426.67 is 43206% above median its 10-year median of 14.84. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 7,190.00. The Biotechnology industry median PS Ratio is 9.37. Avalo Therapeutics' value of 6,426.67 is 68487.7% above this industry median. Based on the distribution chart, Avalo Therapeutics ranks #930 out of 935 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avalo Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avalo Therapeutics' PS Ratio compare to SANA and ANRO?
According to the Biotechnology industry distribution chart, Avalo Therapeutics ranks #930 out of 935 companies for PS Ratio. This places Avalo Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.37. Avalo Therapeutics' value of 6,426.67 is 68487.7% above this benchmark. Historically, Avalo Therapeutics' own PS Ratio has ranged from 0.05 to 7,190.00 over the past decade. While the company's 10-year median is 14.84 vs. the industry median of 9.37, Avalo Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.37, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avalo Therapeutics's current PS Ratio of 6,426.67 is 68487.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Avalo Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avalo Therapeutics's current PS Ratio is 6,426.67, which is 43206% above median its own 10-year median of 14.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Avalo Therapeutics (AVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $19.28 — trading 64166.7% above its estimated fair value. The current PS Ratio is 6,426.67, which is 43206% above median its 10-year median of 14.84 and 68487.7% above the Biotechnology industry median of 9.37. Avalo Therapeutics' overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Avalo Therapeutics (AVTX), the current PS Ratio is 6,426.67 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avalo Therapeutics (AVTX) Overvalued in 2026?
Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued.
The current stock price of $19.28 is trading 64166.7% above its estimated GF Value™ of $0.03.
GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.
Key valuation signals for AVTX:
PS Ratio: 6,426.67 (43206% above median its 10-year median of 14.84)
GF Value™: $0.03 vs. price of $19.28 (64166.7% above fair value)
Industry Position: 68487.7% above the Biotechnology median (#930 of 935)
No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
23GF Score
Get the complete analysis for AVTX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVTX has been successfully added to your 
